AdaptVac

Executive Summary

AdaptVac is a Danish biotechnology company pioneering capsid Virus-Like Particle (cVLP) display technology for next-generation vaccines targeting oncology, infectious diseases, and immunological disorders. Its proprietary platform enables potent and durable immune responses, validated through a Phase 3 COVID-19 vaccine program. The company is advancing a pipeline of therapeutic and prophylactic vaccine candidates, leveraging cVLP's ability to display multiple antigens in a highly immunogenic format. With a strong IP position and clinical proof-of-concept, AdaptVac is poised to address high medical needs in areas such as cancer and persistent viral infections.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2/3 trial for therapeutic cancer vaccine candidate65% success
• Q2 2026Announcement of new partnership or licensing deal for cVLP platform60% success
• Q1 2026Publication of preclinical data on next-generation cVLP constructs in peer-reviewed journal80% success